References
- Appelbaum FR. The current status of hematopoietic cell transplantation. Annu Rev Med 2003;54:491–512.
- Tabbara IA, Zimmerman K, Morgan C, et al. Allogeneic hematopoietic stem cell transplantation: complications and results. Arch Intern Med 2002;162:1558–1566.
- Deeg HJ. How I treat refractory acute GVHD. Blood 2007;109: 4119–4126.
- Couriel D, Saliba R, Hicks K, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004;104:649–654.
- Kebriaei P, Isola L, Bahceci E, et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009;15: 804–811.
- Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008;371:1579–1586.
- Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006;81:1390–1397.
- Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945–956.
- Devergie A. Graft versus host disease. In: Apperley J, Carreras E, Gluckman E, et al., editors. EBMT-ESH handbook on haematopoietic stem cell transplantation. Paris: ESH; 2008. Ch 11.
- Minguell JJ, Erices A, Conget P. Mesenchymal stem cells. Exp Biol Med (Maywood) 2001;226:507–520.
- Blande IS, Bassaneze V, Lavini-Ramos C, et al. Adipose tissue mesenchymal stem cell expansion in animal serum-free medium supplemented with autologous human platelet lysate. Transfusion 2009;49:2680–2685.
- Schallmoser K, Strunk D. Preparation of pooled human platelet lysate (pHPL) as an efficient supplement for animal serum-free human stem cell cultures. J Vis Exp 2009;(32). pii:. 1523.
- von Bahr L, Sundberg B, Lonnies L, et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 2012;18:557–564.
- Lucchini G, Introna M, Dander E, et al. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant 2010;16:1293–1301.